{"resourceType": "EvidenceVariable", "url": "https://fevir.net/resources/EvidenceVariable/346487", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "urn:ietf:rfc:3986", "value": "https://fevir.net/FOI/346487", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "CTIS2024-516402-32-00 Primary Outcome 1", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "CTIS endPoint id"}, "value": 441508}], "name": "CTIS2024_516402_32_00_Primary_Outcome_1", "title": "CTIS2024-516402-32-00 Primary Outcome 1", "status": "active", "description": "Response to therapy, defined by the absence of any of the following events: i) at 6-month follow-up: persistent renal replacement therapy, eGFR<15ml/mn/1,73m2, or patient death; ii) at W2 : persistent hemolysis despite well conducted antihypertensive therapy. Any Eculizumab rescue in the control group will be considered as a failure.", "meta": {"versionId": "1", "lastUpdated": "2025-03-05T18:20:38.916Z"}, "id": "346487", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "author": [{"name": "Brian S. Alper, MD, MSPH"}]}